Compound Detail
CHEMBL535
SUNITINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL535 |
| Name | SUNITINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WINHZLLDWRZWRT-ATVHPVEESA-N |
| Therapeutic | ✓ Yes |
603
Targets
1,915
Activities
4
Assay Types
30
PK Parameters
20
Publications
7
Known Names
20
Indications
9
Mechanisms
Molecular Properties
398.5
MW (Da)
3.33
ALogP
3
HBA
3
HBD
77.2
PSA (Ų)
0.63
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2006 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Macrophage colony stimulating factor receptor inhibitor | INHIBITOR | Macrophage colony-stimulating factor 1 receptor | ✓ | ✓ |
| Vascular endothelial growth factor receptor 2 inhibitor | INHIBITOR | Vascular endothelial growth factor receptor 2 | ✓ | ✓ |
| Stem cell growth factor receptor inhibitor | INHIBITOR | Mast/stem cell growth factor receptor Kit | ✓ | ✓ |
| Platelet-derived growth factor receptor beta inhibitor | INHIBITOR | Platelet-derived growth factor receptor beta | ✓ | ✓ |
| Platelet-derived growth factor receptor alpha inhibitor | INHIBITOR | Platelet-derived growth factor receptor alpha | ✓ | ✓ |
| Vascular endothelial growth factor receptor 1 inhibitor | INHIBITOR | Vascular endothelial growth factor receptor 1 | ✓ | ✓ |
| Vascular endothelial growth factor receptor 3 inhibitor | INHIBITOR | Vascular endothelial growth factor receptor 3 | ✓ | ✓ |
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Tyrosine-protein kinase receptor RET inhibitor | INHIBITOR | Proto-oncogene tyrosine-protein kinase receptor Ret | ✓ | ✓ |
Indications
Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Gastrointestinal Stromal Tumors Neoplasms Neoplasms Neuroendocrine Tumors Neuroendocrine Tumors Breast Neoplasms Breast Neoplasms Carcinoma, Non-Small-Cell Lung Kidney Neoplasms Kidney Neoplasms Prostatic Neoplasms Prostatic Neoplasms Urogenital Neoplasms Adenocarcinoma Adrenal Cortex Neoplasms Ascites
ATC Classification
L01EX01
sunitinib
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Activity Summary
Kd 977 meas. best 10.12
IC50 891 meas. best 9.56
EC50 33 meas. best 7.84
Ki 14 meas. best 8.7
Target Activity Profile
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 438.33 | ng.hr.mL-1 | Mus musculus |
| AUC | 7202.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 23994.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 11848.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1063.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1099.0 | ng.hr.mL-1 | Macaca fascicularis |
| AUC | 1453.0 | ng.hr.mL-1 | Macaca fascicularis |
| CL | 13.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 21.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 58.0 | mL.min-1.g-1 | Mus musculus |
| Cmax | 320.0 | nM | Mus musculus |
| Cmax | 4574.88 | nM | Rattus norvegicus |
| Cmax | 3144.45 | nM | Rattus norvegicus |
| Cmax | 2416.68 | nM | Rattus norvegicus |
| Cmax | 61.23 | nM | Homo sapiens |
| Cmax | 208.29 | nM | Macaca fascicularis |
| Cmax | 230.88 | nM | Macaca fascicularis |
| Fu | 0.007 | - | Rattus norvegicus |
| Fu | 0.009 | - | Rattus norvegicus |
| T1/2 | 0.08333 | hr | Homo sapiens |
| T1/2 | 0.08333 | hr | Homo sapiens |
| T1/2 | 0.08333 | hr | Homo sapiens |
| T1/2 | 0.08333 | hr | Homo sapiens |
| T1/2 | 0.1833 | hr | Mus musculus |
| T1/2 | 0.5 | hr | Homo sapiens |
| T1/2 | 0.1883 | hr | Homo sapiens |
| T1/2 | 0.735 | hr | Homo sapiens |
| T1/2 | 0.205 | hr | Mus musculus |
| T1/2 | 0.4417 | hr | Rattus norvegicus |
| T1/2 | 7.4 | hr | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 18077425 | 10.1073/pnas.0707498104 | NON-PROTEIN TARGET | 210 |
| 31250638 | 10.1021/acs.jmedchem.9b00280 | Mast/stem cell growth factor receptor Kit | 49 |
| 33797247 | 10.1021/acs.jmedchem.0c02247 | MOLM-13 | 40 |
| 30968693 | 10.1021/acs.jmedchem.8b01845 | Mast/stem cell growth factor receptor Kit | 29 |
| 31721578 | 10.1021/acs.jmedchem.9b01229 | Mast/stem cell growth factor receptor Kit | 27 |
| 33797247 | 10.1021/acs.jmedchem.0c02247 | MV4-11 | 26 |
| 26254279 | 10.18632/oncotarget.4214 | Unchecked | 18 |
| 30204441 | 10.1021/acs.jmedchem.8b00938 | Mast/stem cell growth factor receptor Kit | 16 |
| 22037378 | 10.1038/nbt.1990 | Tyrosine-protein kinase ABL1 | 15 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 18077425 | 10.1073/pnas.0707498104 | COLO | 14 |
| 21885287 | 10.1016/j.bmc.2011.08.002 | Vascular endothelial growth factor receptor 2 | 14 |
| 31250638 | 10.1021/acs.jmedchem.9b00280 | Unchecked | 13 |
| 22180047 | 10.1124/dmd.111.042853 | Rattus norvegicus | 13 |
| 19740074 | 10.1042/bj20091035 | Leucine-rich repeat serine/threonine-protein kinase 2 | 12 |
| 30742435 | 10.1021/acs.jmedchem.8b01714 | Receptor-type tyrosine-protein kinase FLT3 | 12 |
| 22180047 | 10.1124/dmd.111.042853 | ADMET | 12 |
| 26629594 | 10.1021/acs.jmedchem.5b01582 | BaF3 | 12 |
| 22037378 | 10.1038/nbt.1990 | Epidermal growth factor receptor | 12 |
| 22037378 | 10.1038/nbt.1990 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 10 |
Data from ChEMBL 36 via Core Engine